Legaspi, Hannilore V.
HRN: 04-64-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/18/2025
CEFUROXIME 500MG (TAB)
04/18/2025
04/25/2025
ORAL
500mg
BID
Sp NSVD With RMLE
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes